GLP-1(32-36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs

Peptides

Volumn 59, Issue , 2014, Pages 20-24

  Elahi, Dariush ^a   Angeli, Franca S ^a   Vakilipour, Amin ^a   Carlson, Olga D ^b   Tomas, Eva ^c   Egan, Josephine M ^b   Habener, Joel F ^c   Shannon, Richard P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diabetes; Glucagon like peptide 1; Glucose utilization; Insulin resistance; Obesity

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [32-36] AMIDE; GLUCOSE; INSULIN; PENTAPEPTIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLP-1(32-36)AMIDE; GLUCOSE BLOOD LEVEL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANINE MODEL; CATHETERIZATION; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL DOG; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MODULATION; NONHUMAN; PRIORITY JOURNAL; STIMULATION; AREA UNDER THE CURVE; CONTINUOUS INFUSION; DOG; DRUG INFUSION; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; RANK SUM TEST; STUDENT T TEST; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; BLOOD GLUCOSE; DOGS; GLUCAGON-LIKE PEPTIDE 1;

EID: 84904541595     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2014.06.004     Document Type: Article

References (32)

1. R. Abu-Hamdah, A. Rabiee, G.S. Meneilly, R.P. Shannon, D.K. Andersen, and D. Elahi Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides J Clin Endocrinol Metab 94 2009 1843 1852
2. R. Andres, R. Swerdloff, T. Pozefsky, and D. Coleman Manual feedback technique for control of glucose concentration L. Skeggs Jr. Automation in analytic chemistry 1966 Medaid, Inc. New York 486 501
3. F.S. Angeli, and R.P. Shannon Incretin based therapies: can we achieve glycemic control and cardioprotection? J Endocrinol 2013 10.1530/JOE-13-0195
4. K. Ban, K.H. Kim, C.K. Cho, M. Sauve, E.P. Diamandis, and P.H. Backx et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor Endocrinology 151 2010 1520 1531
5. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350 (Pubitemid 351653542)
6. C.F. Deacon, A. Plamboeck, S. Moller, and J.J. Holst GLP-1(9-36)amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion Am J Physiol Endocrinol Metab 282 April (4) 2002 E873 E879
7. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 9548 2006 1696 1705 (Pubitemid 46048557)
8. D. Elahi, J.M. Egan, R.P. Shannon, G.S. Meneilly, A. Khatri, and J.F. Habener et al. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide Obesity (Silver Spring, Md.) 16 2008 1501 1509 (Pubitemid 351915102)
9. A. Flint, A. Raben, A. Astrup, and J.J. Holst Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 101 1998 515 520 (Pubitemid 28084232)
10. D.G. Hardie Energy sensing by the AMP-activated protein kinase and its effects on muscle metabolism Proc Nutr Soc 70 2011 92 99
11. K. Hupe-Sodmann, G.P. McGregor, R. Bridenbaugh, R. Goke, B. Goke, and H. Thole et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides Regul Pept 58 1995 149 156
12. W. Ip, W. Shao, Y.T. Chiang, and T. Jin GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice Am J Physiol Endocrinol Metab 305 December (11) 2013 E1348 E1358
13. T.J. Kieffer, and J.F. Habener The glucagon-like peptides Endocr Rev 20 1999 876 913 (Pubitemid 30647076)
14. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
15. P.J. Larsen, C. Fledelius, L.B. Knudsen, and M. Tang-Christensen Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats Diabetes 50 2001 2530 2539 (Pubitemid 33642771)
16. C.J. Lee, T. Brown, T.H. Magnuson, J.M. Egan, O. Carlson, and D. Elahi Hormonal response to a mixed-meal challenge after reversal of gastric bypass for hypoglycemia J Clin Endocrinol Metab 98 2013 E1208 E1212
17. Z. Liu, V. Stanojevic, L.J. Brindamour, and J.F. Habener GLP-1-derived nonapeptide GLP-1(28-36)amide protects pancreatic beta-cells from glucolipotoxicity J Endocrinol 213 2012 143 154
18. J.J. Meier, A. Gethmann, M.A. Nauck, O. Gotze, F. Schimtz, and C.F. Deacon et al. The glucagon-like peptide-1 metabolite GLP-1(9-36)amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans Am J Physiol Endocrinol Metab 290 June (6) 2006 E1118 E1123
19. L.A. Nikolaidis, D. Elahi, Y.T. Shen, and R.P. Shannon Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy Am J Physiol Heart Circ Physiol 289 2005 H2401 H2408
20. G.S. Price, and D.L. Frazier Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae J Vet Intern Med/Am Coll Vet Intern Med 12 1998 267 271
21. A. Rabiee, J.T. Magruder, C. Grant, R. Salas-Carrillo, A. Gillette, and J. DuBois et al. Accuracy and reliability of the Nova StatStrip(R) glucose meter for real-time blood glucose determinations during glucose clamp studies J Diab Sci Technol 4 2010 1195 1201
22. I. Salcedo, D. Tweedie, Y. Li, and N.H. Greig Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders Br J Pharmacol 166 2012 1586 1599
23. M. Sathananthan, L.P. Farrugia, J.M. Miles, F. Piccinini, C. Dalla Man, and A.R. Zinsmeister et al. Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, beta-cell function, and glucose metabolism in nondiabetic subjects Diabetes 62 8 2013 2752 2756
24. W. Shao, Z. Wang, W. Ip, Y.T. Chiang, X. Xiong, and T. Chai et al. GLP-1(28-36) improves beta-cell mass and glucose disposal in streptozotocin induced diabetes mice and activates PKA-beta-catenin signaling in beta-cells in vitro Am J Physiol 2013 10.1152/ajpendo.00600.2012
25. D.P. Sonne, T. Engstrom, and M. Treiman Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart Regul Pept 146 2008 243 249
26. E. Tomas, and J.F. Habener Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis Trends Endocrinol Metab 21 2010 59 67
27. E. Tomas, V. Stanojevic, and J.F. Habener GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes Horm Metab Res 42 2010 657 662
28. E. Thomas, J.A. Wood, V. Stanojevic, and J.F. Habener Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice Diab Obes Metab 13 2011 26 33
29. E. Tomas, V. Stanojevic, and J.F. Habener GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes Regul Pept 167 2011 177 184
30. E. Tomas, J.A. Wood, V. Stanojevic, and J.F. Habener GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice Regul Pept 169 2011 43 48
31. E. Tomas, V. Stanojevic, R. Laudone, P. Everill, W. Bachovchin, and J.F. Habener GLP-1-derived pentapeptide GLP-1(32-36)amide attenuates the development of obesity, diabetes, hepatic steatosis, and increases energy expenditure in diet-induced obese mice [abstract] Diabetes 61 Suppl. 2012 1915-P
32. +/NADH ratio in C2C12 myotubes Diabetes 63 Suppl. 2014 1857-P